Pathogenesis of Myocardial Ischemia-reperfusion Injury and Rationale for Therapy

Overview

Journal Am J Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Jul 21

PMID 20643246

Citations 257

Authors

Aslan T Turer

Joseph A Hill

Affiliations

Soon will be listed here.

Abstract

Since the initial description of the phenomenon by Jennings et al 50 years ago, our understanding of the underlying mechanisms of reperfusion injury has grown significantly. Its pathogenesis reflects the confluence of multiple pathways, including ion channels, reactive oxygen species, inflammation, and endothelial dysfunction. The purposes of this review are to examine the current state of understanding of ischemia-reperfusion injury, as well as to highlight recent interventions aimed at this heretofore elusive target. In conclusion, despite its complexity our ongoing efforts to mitigate this form of injury should not be deterred, because nearly 2 million patients annually undergo either spontaneous (in the form of acute myocardial infarction) or iatrogenic (in the context of cardioplegic arrest) ischemia-reperfusion.

Citing Articles

Potential of Polydatin Against Ischemia-Reperfusion Injury: New Insights from Pharmacological-Pathological Mechanism Associations.

Sun Z, Wang X, Pang X Drug Des Devel Ther. 2025; 19:1585-1594.

PMID: 40066082 PMC: 11892733. DOI: 10.2147/DDDT.S508851.

Molecular Insights into Ischemia-Reperfusion Injury in Coronary Artery Disease: Mechanisms and Therapeutic Implications: A Comprehensive Review.

Ghanta S, Kattamuri L, Odueke A, Mehta J Antioxidants (Basel). 2025; 14(2).

PMID: 40002399 PMC: 11851988. DOI: 10.3390/antiox14020213.

Association between diabetes and heart failure after coronary artery bypass grafting: Danish register-based cohort study.

Brodersen B, Kristiansen L, le Fevre Karlsen S, Hauch J, Andreasen J, Kragholm K Clin Res Cardiol. 2025; .

PMID: 39992384 DOI: 10.1007/s00392-025-02594-8.

MicroRNA-221 protects myocardial contractility in myocardial ischemia/reperfusion injury through phospholamban.

Li H, Qiu J, Liu C, Yu G, Wu D, Chu Y PLoS One. 2025; 20(1):e0316887.

PMID: 39883723 PMC: 11781681. DOI: 10.1371/journal.pone.0316887.

Profiling and bioinformatics analyses of circular RNAs in myocardial ischemia/reperfusion injury model in mice.

Wang J, Zhou Y, Yu Y, Chen J World J Cardiol. 2025; 17(1):102147.

PMID: 39866220 PMC: 11755133. DOI: 10.4330/wjc.v17.i1.102147.

References

Mangano D, Miao Y, Tudor I, Dietzel C . Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006; 48(1):206-14. DOI: 10.1016/j.jacc.2006.04.044. View

Leung J, Stanley 3rd T, Mathew J, Curling P, Barash P, Salmenpera M . An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. Anesth Analg. 1994; 78(3):420-34. DOI: 10.1213/00000539-199403000-00002. View

Chao W . Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2008; 296(1):H1-12. PMC: 2637783. DOI: 10.1152/ajpheart.00995.2008. View

Prunier F, Pfister O, Hadri L, Liang L, Monte F, Liao R . Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2006; 292(1):H522-9. DOI: 10.1152/ajpheart.00357.2006. View

Alexander J, Emery Jr R, Carrier M, Ellis S, Mehta R, Hasselblad V . Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008; 299(15):1777-87. DOI: 10.1001/jama.299.15.joc80027. View

Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A . Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005; 95(11):1358-61. DOI: 10.1016/j.amjcard.2005.01.082. View

Weman S, Karhunen P, Penttila A, Jarvinen A, Salminen U . Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg. 2000; 70(3):807-12. DOI: 10.1016/s0003-4975(00)01638-6. View

Henriques J, Zijlstra F, van t Hof A, de Boer M, Dambrink J, Gosselink M . Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003; 107(16):2115-9. DOI: 10.1161/01.CIR.0000065221.06430.ED. View

Assali A, Sdringola S, Ghani M, Denkats A, Yepes A, Hanna G . Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no reflow" phenomenon. Catheter Cardiovasc Interv. 2000; 51(1):27-31; discussion 32. DOI: 10.1002/1522-726x(200009)51:1<27::aid-ccd7>3.0.co;2-0. View

10.

Shaw A, Stafford-Smith M, White W, Phillips-Bute B, Swaminathan M, Milano C . The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008; 358(8):784-93. DOI: 10.1056/NEJMoa0707768. View

11.

Murry C, Jennings R, Reimer K . Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74(5):1124-36. DOI: 10.1161/01.cir.74.5.1124. View

12.

Tassani P, Richter J, Barankay A, Braun S, Haehnel C, Spaeth P . Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?. J Cardiothorac Vasc Anesth. 1999; 13(2):165-72. DOI: 10.1016/s1053-0770(99)90081-2. View

13.

Olivencia-Yurvati A, Blair J, Baig M, Mallet R . Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003; 17(6):715-20. DOI: 10.1053/j.jvca.2003.09.007. View

14.

Kandzari D, Dery J, Armstrong P, Douglas D, Zettler M, Hidinger G . MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs. 2005; 14(11):1435-42. DOI: 10.1517/13543784.14.11.1435. View

15.

Verrier E, Shernan S, Taylor K, Van de Werf F, Newman M, Chen J . Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004; 291(19):2319-27. DOI: 10.1001/jama.291.19.2319. View

16.

Staat P, Rioufol G, Piot C, Cottin Y, Cung T, LHuillier I . Postconditioning the human heart. Circulation. 2005; 112(14):2143-8. DOI: 10.1161/CIRCULATIONAHA.105.558122. View

17.

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P . Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100(8):4802-6. PMC: 153636. DOI: 10.1073/pnas.0630444100. View

18.

Schneider C, Jaquet K, Malisius R, Geidel S, Bahlmann E, Boczor S . Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J. 2007; 28(4):499-509. DOI: 10.1093/eurheartj/ehl439. View

19.

Leal-Noval S, Amaya R, Herruzo A, Hernandez A, Ordonez A, Marin-Niebla A . Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: a controlled randomized trial. Ann Thorac Surg. 2005; 80(4):1394-400. DOI: 10.1016/j.athoracsur.2005.04.021. View

20.

Gao E, Boucher M, Chuprun J, Zhou R, Eckhart A, Koch W . Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007; 293(1):H60-8. DOI: 10.1152/ajpheart.00227.2007. View